Endo’s Next Chapter Will Be Led By CEO De Silva
This article was originally published in The Pink Sheet Daily
Former Valeant President De Silva joins Endo in the midst of a challenging year for the company, as two top-selling drugs face generic competition. De Silva will need to reenergize Endo and do so quickly if he is to maintain the early favor he appears to have won from investors.
You may also be interested in...
Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.
Endo confirmed March 11 that it has offered to acquire the GI specialist for $175 per share, trumping Valeant’s $158 per share offer announced in February.
Endo seals the deal with Auxilium in a $2.6 billion acquisition that will add to its men’s health business and won’t prevent it from continuing on its M&A spree.